GlobeNewsWire
02 Jun 2026, 23:05 UTC · 17w ago
Verdict
Headline takes no side. We score ZBIO +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The Phase 3 INDIGO trial for obexelimab in IgG4-RD met its primary endpoint and all key secondary endpoints with statistically significant results.
More positive than 99% of claims this week
Zenas BioPharma submitted a Biologics License Application (BLA) for obexelimab to the FDA in May.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 93% of claims this week
Obexelimab significantly reduced glucocorticoid use and related toxicities with a safety profile comparable to placebo.
More positive than 79% of claims this week
The company expects to report topline results from its Phase 2 SunStone SLE trial later this year.
So whatThis provides a secondary catalyst for the stock, expanding the potential addressable market beyond IgG4-RD into Systemic Lupus Erythematosus (SLE).
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced successful Phase 3 trial results for obexelimab, meeting all primary and key secondary endpoints.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
9h ago
+56.2%
Price agrees with the score
$26.76 vs $17.13 close before publication (Jun 2) · not market-adjusted
ZBIO chart →
